Private Equity & Investor Services
Value creation across the full deal lifecycle
Investments in life sciences and healthcare are becoming increasingly complex. Investors are facing rising pressure to deploy capital effectively, validate investment theses quickly and deliver measurable value within shorter holding periods.
At the same time, sector-specific dynamics such as regulatory complexity, reimbursement systems, fragmented provider landscapes and operational constraints require deep industry expertise. Successful investments depend not only on identifying attractive assets, but on the ability to translate investment theses into scalable operating models and measurable EBITDA impact.
ZEQ supports private equity investors, portfolio companies and management teams across the entire investment lifecycle. From pre-deal search and evalutaion, to post-merger integration, value creation programs and exit readiness, we help turn strategic intent into execution and support sustainable value realization.
Private Equity in Life Sciences & Healthcare between deal pressure and execution complexity
The sector is characterized by a combination of strong investment activity and operational complexity. Typical challenges include:
- High pressure on deal quality: Investment decisions require a robust understanding of market dynamics, regulatory risks and scalability potential.
- Execution risk post-close: Value creation depends on the ability to quickly establish transparency, governance and operational control.
- Fragmented and regulated markets: Healthcare and life sciences assets require deep understanding of the market and stakeholder dynamics as well as structural reforms and reimbursement logic for healthcare services and products
- Limited scalability without transformation: Growth often requires operating model adjustments, digital enablement and process standardization.
- Increasing expectations at exit: Buyers demand clear evidence of value creation, operational maturity and scalable structures.
ZEQ supports investors in addressing these challenges across the full deal lifecycle — from target evaluation to exit.
Where we create impact
We create impact where investment logic meets operational reality. Successful investments in healthcare and life sciences require a consistent link between diligence, execution and value realization.
In the pre-deal phase, we support target searches and outside-in assessments to evaluate new healthcare investment themes and enable a rapid go/no-go perspective ahead of potential due diligence.
During the transaction phase, ZEQ provides CDD, market DD and ODD support to strengthen the investment case, pressure-test downside risks, and minimize value leakage and execution risk after closing.
After closing, we support the post-merger integration. This includes e.g. 100-day planning, the implementation of governance and KPI-based steering models to give operating partners early control and transparency, while prioritizing quick wins and structural value-creation moves
At exit, we help make value creation visible and credible. We support equity story development, KPI transparency and vendor due diligence preparation to reduce uncertainty and increase transaction efficiency.
ZEQ is your specialist M&A value creation partner across the deal lifecycle
We support investors and portfolio companies across the entire deal lifecycle — from initial target assessment to exit preparation. Our approach is based upon a consistent fact base, clear prioritization and seamless transition from diligence to execution.
By linking strategic analysis with operational implementation, we help translate investment thesis into measurable value.
Pre-Deal
We help investors identify attractive healthcare opportunities and develop an early view on strategic fit before entering full diligence.
Key Activities
- Target search in relevant healthcare and life sciences segments
- Outside-in evaluation of market attractiveness and strategic fit
- Initial assessment of growth potential, risks and deal relevance
Outcomes / Value Added
- New ideas for potential investment targets
- Fast go / no-go perspective for further due diligence
- Early prioritization of the most promising opportunities
Deal & Acquisition
We support investment decisions with a healthcare-native diligence approach, combining market, commercial and operational perspectives.
Key Activities
- Commercial and market due diligence, including market sizing, growth drivers and competitive dynamics
- Customer, reimbursement and regulatory assessment, including stakeholder voice and reform exposure for healthcare assets
- Operational baseline assessment, including EBITDA levers, risks and post-close requirements
Outcomes / Value Added
- Better-informed investment decision with a clearer downside case
- Early identification of red flags before signing
- Reduced value leakage and execution risk post-close
Post-Merger Integration & Transformation
We translate the investment thesis into a structured execution setup with clear priorities, governance and measurable progress.
Key Activities
- Post-merger integration planning and execution across business and back-office functions
- Setup of the PMO / Execution Office with governance, milestones and KPI tracking
- Development of a 100-day plan with quick wins and structural moves
- Initiation of synergy tracking and execution of value creation initiatives
Outcomes / Value Added
- Early control and transparency for operating partners
- Fast capture of quick wins without overloading management and teams
- Prioritized execution roadmap balancing quick wins and structural moves
Scale
We support portfolio companies in scaling platforms, integrating acquisitions and realizing measurable value creation.
Key Activities
- Buy-and-build and PMI support, including integration blueprint and synergy tracking
- Setup of revenue growth and value creation programs across growth, cost, efficiency, digital and data
- Development of digital and KPI cockpits for transparent steering and board reporting
Outcomes / Value Added
- Measurable margin uplift with operational control
- Faster integration and synergy capture with lower operational disruption
- Standardized KPI definitions and scalable structures as foundation for exit
Exit
We help make the value creation journey visible, credible and well documented for potential buyers.
Key Activities
- Facilitation of exit readiness sprints and preparation of management narrative
- Development of a compelling equity story and KPI book
- Sell-side due diligence and Q&A support with data room-ready materials
Outcomes / Value Added
- Higher credibility of the value creation journey
- Fewer buyer questions on operations, quality and compliance
- Faster process with cleaner diligence workstreams
What sets us apart
We combine deep healthcare and life sciences expertise with pragmatic execution support. Our senior-led, interdisciplinary teams bring together clinicians, economists and experienced marketeers, enabling us to assess market dynamics, scalability and operational realities with a high level of sector understanding.
Our work is focused on measurable value creation. We translate strategic opportunities into quantified EBITDA bridges, initiative roadmaps, clear owners, KPIs and timelines. This gives investors, operating partners and management teams a reliable basis for decision-making and execution.
By working closely with our clients throughout the process, strategies, operating models and value creation initiatives become realistic, prioritized and anchored within the organization. One integrated team and one consistent fact base provide continuity from initial diligence to exit preparation.
This is reflected in three core strengths:
- Senior-led, healthcare-native diligence and execution
- Quantified value creation with clear governance and KPIs
- Practical implementation support across the full deal lifecycle
In Life Sciences and Healthcare, value is not created by strategy alone. It is created through clear priorities, operational discipline and consistent execution across the entire deal lifecycle.
Dr. Isabelle Heiber
Head of M&A and Private Equity
